Posted by Michael Wonder on 22 Nov 2016
Novo Nordisk receives US FDA approval for Xultophy 100/3.6
21 November 2016 - Novo Nordisk today announced that the US FDA has approved the new drug application for Xultophy 100/3.6.
Xultophy 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).
